International Isotopes INC (INIS) — SEC Filings

Overview

International Isotopes INC (INIS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: International Isotopes Inc. filed an 8-K on December 23, 2025, reporting on amendments to its articles of incorporation or bylaws, other events, and financial statements. The filing details the company's principal executive offices located at 4137 Commerce Circle, Idaho Falls, ID 83401, with a busin

Sentiment Summary

Across 19 filings, the sentiment breakdown is: 1 bearish, 17 neutral, 1 mixed. The dominant filing sentiment for International Isotopes INC is neutral.

Filing Type Overview

International Isotopes INC (INIS) has filed 6 8-K, 6 10-Q, 3 DEF 14A, 1 10-K/A, 2 10-K, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (19)

• International Isotopes Inc. Files 8-K — 8-K · Dec 31, 2025 Risk: low
  International Isotopes Inc. filed an 8-K on December 23, 2025, reporting on amendments to its articles of incorporation or bylaws, other events, and financial s
• INIS Swings to Loss Amidst Revenue Dip, Eyes $12.5M Asset Sale — 10-Q · Nov 14, 2025 Risk: high
  INTERNATIONAL ISOTOPES INC. (INIS) reported a net loss of $203,601 for the three months ended September 30, 2025, a significant decline from a net income of $15
• Intl Isotopes Files 8-K: Officer/Director Changes & Bylaw Amendments — 8-K · Oct 17, 2025 Risk: medium
  International Isotopes Inc. filed an 8-K on October 17, 2025, reporting events as of October 10, 2025. The filing indicates changes related to the departure of
• INIS Narrows Losses Amid Revenue Growth, Strategic Shifts — 10-Q · Aug 13, 2025 Risk: medium
  INTERNATIONAL ISOTOPES INC (INIS) reported a net loss of $273,479 for the six months ended June 30, 2025, an improvement from a net loss of $387,496 in the same
• International Isotopes Inc. Reports on Shareholder Votes — 8-K · Jul 16, 2025 Risk: low
  International Isotopes Inc. filed an 8-K on July 16, 2025, reporting on matters submitted to a vote of security holders as of July 10, 2025. The filing details
• INIS Details Executive Equity Compensation for 2024 — DEF 14A · May 27, 2025 Risk: medium
  INTERNATIONAL ISOTOPES INC (INIS) filed a DEF 14A on May 27, 2025, detailing executive compensation for the fiscal year ended December 31, 2024. The filing prim
• International Isotopes Q1 2025: Assets $524.8M, Liabilities $523.6M — 10-Q · May 15, 2025 Risk: medium
  International Isotopes Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements show total assets of $524,794,326
• International Isotopes Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
  International Isotopes Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, headquartered in Idaho Fa
• International Isotopes Inc. Files 2024 10-K — 10-K · Mar 4, 2025 Risk: medium
  International Isotopes Inc. reported its fiscal year 2024 results, ending December 31, 2024. The company's total assets were $523,553,435, with total liabilitie
• International Isotopes Inc. Q3 2024 Update — 10-Q · Nov 12, 2024 Risk: medium
  International Isotopes Inc. reported its Q3 2024 results, with revenue for the nine months ending September 30, 2024, totaling $5,250,000. The company's total a
• Intl Isotopes Files 8-K on Security Holder Rights — 8-K · Oct 2, 2024 Risk: medium
  International Isotopes Inc. filed an 8-K on October 2, 2024, reporting material modifications to security holder rights and amendments to its articles of incorp
• International Isotopes Inc. Q2 2024: Assets $523M, Liabilities $28M — 10-Q · Aug 14, 2024 Risk: medium
  International Isotopes Inc. reported its Q2 2024 financial results, with total assets reaching $522,957,618 as of June 30, 2024. The company's total liabilities
• International Isotopes Inc. Files 8-K on Shareholder Vote — 8-K · Jul 16, 2024 Risk: low
  International Isotopes Inc. filed an 8-K on July 16, 2024, reporting on a matter submitted to a vote of security holders on July 10, 2024. The filing does not p
• International Isotopes Inc. Files Proxy Statement — DEF 14A · May 21, 2024 Risk: low
  International Isotopes Inc. filed a Definitive Additional Materials proxy statement on May 21, 2024, related to its annual meeting on July 10, 2024. The company
• International Isotopes Inc. Files Q1 2024 10-Q Report — 10-Q · May 15, 2024 Risk: low
  INTERNATIONAL ISOTOPES INC (INIS) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Revenue for the three months ended March 31, 2024, was $1,103,42
• SC 13G/A Filing — SC 13G/A · Apr 29, 2024
• International Isotopes Inc. Files Definitive Proxy Statement — DEF 14A · Apr 29, 2024 Risk:
  INTERNATIONAL ISOTOPES INC (INIS) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. International Isotopes Inc. filed a DEF 14A form on April 29
• International Isotopes Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
  INTERNATIONAL ISOTOPES INC (INIS) filed a Annual Report (10-K) with the SEC on March 29, 2024. International Isotopes Inc. reported total assets of $519,787,870
• INTERNATIONAL ISOTOPES Files 8-K: Material Agreement, Details Pending — 8-K · Feb 8, 2024 Risk: medium
  INTERNATIONAL ISOTOPES INC. filed an 8-K on February 8, 2024, indicating an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While t

Risk Profile

Risk Assessment: Of INIS's 17 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from International Isotopes INC's most recent 10-Q filing (Nov 14, 2025):

• Revenue: $10,172,036
• Net Income: -$477,080
• EPS: N/A
• Debt-to-Equity: 3.36
• Cash Position: $1,651,548
• Operating Margin: -63.84%
• Total Assets: $17,846,637
• Total Debt: $13,750,802

Industry Context

The isotope and radiopharmaceutical industry is characterized by high regulatory barriers, specialized manufacturing processes, and a critical role in medical diagnostics and treatments. Companies like INIS operate in a niche market where demand is driven by healthcare needs and scientific research. Competition can be intense, with established players and emerging technologies vying for market share. Trends include the increasing use of targeted therapies and diagnostic imaging, driving demand for specific isotopes.

Top Tags

financials (5) · corporate-governance (4) · 10-Q (3) · amendment (2) · Nuclear Medicine (2) · Asset Sale (2) · Liquidity Risk (2) · SEC Filing (2) · Medical Devices (2) · Isotopes (2)

Executive Compensation

From the most recent DEF 14A filing (May 27, 2025):

• Not Disclosed — Principal Executive Officer (PEO): Not Disclosed
• Not Disclosed — Other Non-PEO Executives: Not Disclosed

Key Numbers

• Net loss for Q3 2025: $203,601 — Compared to $150,251 net income in Q3 2024, indicating a significant swing to loss.
• Net loss for nine months ended Sept 30, 2025: $477,080 — Widened from $237,245 net loss in the same period of 2024.
• Product sales for Q3 2025: $3,277,816 — Decreased from $3,924,444 in Q3 2024.
• Product sales for nine months ended Sept 30, 2025: $10,172,036 — Slightly increased from $9,998,135 in the same period of 2024.
• Net cash provided by operating activities for nine months ended Sept 30, 2025: $210,043 — Significantly decreased from $568,215 in the same period of 2024.
• Proceeds from planned asset sale: $12.5 million — Expected from the sale of Fluorine Products segment and De-Conversion Facility, critical for future liquidity.
• Outside Date for asset sale closing: March 31, 2026 — Deadline for the Fluorine Products segment and De-Conversion Facility sale, subject to conditions.
• Common shares outstanding: 528,209,538 — As of November 12, 2025.
• Event Date: 20251010 — Date of earliest event reported
• Filing Date: 20251017 — Date the report was filed with the SEC
• Product Sales: $6.89M — Increased from $6.07M in 2024 for the six months ended June 30, 2025, showing a 13.5% growth.
• Net Loss: $273K — Reduced from $387K in 2024 for the six months ended June 30, 2025, indicating improved financial performance.
• Net Cash from Operating Activities: $310K — Increased from $288K in 2024 for the six months ended June 30, 2025, demonstrating stronger operational cash generation.
• Potential Sale Proceeds: $12.5M — Expected from the sale of the Fluorine Products segment, critical for future liquidity.
• Common Shares Outstanding: 528,010,308 — As of June 30, 2025, reflecting share dilution from various issuances.

Frequently Asked Questions